P1-pDCs were prevalent in IFN-α-mediated autoimmune diseases (e.g., lupus and psoriasis) [73], whereas P3-pDCs were increased in melanoma and negatively impacted clinical outcomes [84]. This evidence concerns the gene IFNA1 and melanoma.